Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Fineline Cube Jan 11, 2026
Company Drug

ImmuneOnco Biopharmaceuticals’ Timdarpacept (IMM01) Earns Orphan Drug Designation for CMML

Fineline Cube Nov 9, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received orphan drug...

Company Medical Device

Lifetech Scientific Corporation Receives NMPA Approval for Peripheral Thrombus Suction Catheter

Fineline Cube Nov 9, 2023

Lifetech Scientific Corporation (HKG: 1302), a China-based medical device company, has announced that it has...

Company

Bayer’s Q3 2023 Financial Report: A Mixed Bag with Consumer Health Driving Growth

Fineline Cube Nov 9, 2023

Germany-based major Bayer (ETR: BAYN) published its financial report for the third quarter of 2023,...

Company

Viatris Inc. Reports Q3 2023 Global Net Sales Growth of 1% and Highlights from Earnings Call

Fineline Cube Nov 9, 2023

US-based generics giant Viatris Inc., (NASDAQ: VTRS) has released its financial results for the third...

Company Drug

Abbisko Therapeutics’ CD73 Inhibitor ABSK051 Clears for Phase I Clinical Trial in China

Fineline Cube Nov 9, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...

Company Drug

US FDA Approves HutchMed and Takeda’s Fruzaqla for Metastatic Colorectal Cancer Treatment

Fineline Cube Nov 9, 2023

The US Food and Drug Administration (FDA) has granted approval to HutchMed (NASDAQ: HCM) and...

Company Deals

Suzhou Porton Biologics Partners with BioMap to Enhance AAV Vector Design in Gene Therapy

Fineline Cube Nov 9, 2023

Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...

Company Deals

CIIE 2023: Danaher, Boehringer-Ingelheim, Merck, J&J, BeiGene, and Fosun Pharma Announce China Partnerships

Fineline Cube Nov 9, 2023

The 6th China International Import Expo (CIIE) held in Shanghai this week has been a...

Company Deals

Zymeworks and BeiGene Terminate Licensing Agreement for ZW49 ADC

Fineline Cube Nov 8, 2023

Zymeworks Inc. (NASDAQ: ZYME), a Canada-based biotech company, has announced in its Q3 financial report...

Company Deals

Worg Pharmaceuticals Expands into Spain with Acquisition of Diater for EUR 150 Million

Fineline Cube Nov 8, 2023

Worg Pharmaceuticals, a Hangzhou-based developer of allergic drugs, has formally entered the Spanish market by...

Company Drug

Janssen’s Nipocalimab Shows Promising Results in Phase II Rheumatoid Arthritis Trial

Fineline Cube Nov 8, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced the results of...

Company

Gilead Reports Q3 2023 Financials with 1% YOY Revenue Increase and Updates 2023 Outlook

Fineline Cube Nov 8, 2023

Gilead (NASDAQ: GILD) has released its financial results for the third quarter of 2023, showing...

Company Deals

AstraZeneca Expands China Presence with Over 30 Agreements at CIIE

Fineline Cube Nov 8, 2023

At the 6th China International Import Expo (CIIE) in Shanghai, UK-based pharmaceutical giant AstraZeneca plc...

Company

Moderna Initiates Construction of First China-Based Pharmaceutical Plant in Shanghai

Fineline Cube Nov 8, 2023

S-based mRNA specialist, Moderna (NASDAQ: MRNA), has commenced construction on its inaugural pharmaceutical facility in...

Company Deals

Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China

Fineline Cube Nov 8, 2023

Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration...

Company Deals

Eisai Partners with Shanghai Pharmaceuticals for Alzheimer’s Drug Leqembi in China

Fineline Cube Nov 8, 2023

Eisai (TYO: 4523), a Japan-headquartered pharmaceutical company, has entered into a significant partnership with Shanghai...

Company Deals

Bayer and Shanghai Pharmaceuticals Launch Co.Lab to Incubate Life Sciences Innovation in China

Fineline Cube Nov 8, 2023

Bayer, the Germany-headquartered multinational pharmaceutical and life sciences company (ETR: BAYN), has entered into a...

Company Drug

Abbisko Therapeutics Receives FDA Approval for Phase I Study of FGFR4 Inhibitor ABSK012

Fineline Cube Nov 8, 2023

Shanghai-based biotech company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...

Company Deals Medical Device

Fosun Pharmaceutical and Insightec Collaborate on Non-Invasive Brain Treatment Technology

Fineline Cube Nov 7, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a strategic partnership with Israel-based...

Policy / Regulatory

9th National Volume-Based Procurement Round Results in 70% Price Reduction for 41 Drugs

Fineline Cube Nov 7, 2023

The results of the 9th round of China’s national volume-based procurement (VBP) program have been...

Posts pagination

1 … 387 388 389 … 606

Recent updates

  • Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
  • Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
  • Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy
  • RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo
  • Merck Initiates Phase 3 Trial for Calderasib + KEYTRUDA QLEX in KRAS G12C NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.